Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry

Table 2 Background of the D2T RA cases after IPTW adjustment, by treatment types

Numerical variable	TNFi (N = 71)		IL6-Ri (N = 78)		CTLA4-Ig (N = 58)		JAKi (N = 143)		p
Numerical variable	Mean	SE	Mean	SE	Mean	SE	Mean	SE	p
Age	64.5	20.5	68.5	14.8	65.5	19.3	62.2	20.3	0.51
Disease duration (months)	169.1	135.7	171.7	129.3	191.8	152.7	167.5	131.5	0.18
CDAI	28.4	16.0	30.3	18.8	27.6	14.4	27.5	16.5	0.67
HAQ-DI	1.6	0.9	1.6	1.0	1.7	0.9	1.5	1.0	0.46
Dose of MTX (mg/week)	5.0	1.8	5.1	2.0	4.7	1.6	4.7	2.0	0.50
Dose of GC (mg/day)^a	5.8	2.0	6.0	2.1	5.4	2.0	5.5	2.2	0.19
Serum creatinine (mg/dL)	0.9	0.7	0.9	0.8	0.7	0.4	0.7	0.4	0.10

D2T RA difficult-to-treat rheumatoid arthritis, IPTW propensity-based inverse-probability treatment weighted, SE standard error, TNFi tumour necrosis factor inhibitor, IL-6Ri interleukin-6 receptor inhibitor, CTLA4-Ig cytotoxic T-lymphocyte–associated antigen-4 immunoglobulin, JAKi Janus kinase inhibitor, CDAI Clinical Disease Activity Index, HAQ-DI Health Assessment Questionnaire Disability Index, CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAS disease activity score, MTX methotrexate, GC glucocorticoid, ACPA anti-cyclic citrullinated peptide antibody

ISSN: 1478-6362